High expression of 14‑3‑3ơ indicates poor prognosis and progression of lung adenocarcinoma

• Published in: Oncology letters Vol. 24; no. 1; p. 1
• Main Authors: Feng, Junfei, Leng, Jing, Zhao, Changdi, Guo, Jie, Chen, Yongbing, Li, Haifeng
• Format: Journal Article
• Language: English
• Published: Athens Spandidos Publications 01.07.2022; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Adenocarcinoma; Analysis; Biotechnology; Cancer; Cancer therapies; Cell cycle; Cell growth; Chemotherapy; Crizotinib; DNA methylation; Health aspects; Lung cancer; Medical prognosis; Medical research; Mutation; Oncology; Oncology, Experimental; Pathology; Plasmids; Prognosis; Protein binding; Proteins; Signal transduction; Surgery; Tumorigenesis; China
• ISSN: 1792-1074; 1792-1082
• DOI: 10.3892/ol.2022.13323

Lung adenocarcinoma (LUAD) is one of the leading causes of cancer-related death worldwide. 14-3-3o' is an intracellular phosphoserine-binding protein that has been proposed to be involved in tumorigenesis. However, the biofunctional role of 14-3-3o' and its clinicopathological/prognostic significance in LUAD have remained elusive. In the present study, western blot and immunohistochemical analyses of cancer tissues/cells and the corresponding normal controls were performed to verify that 14-3-3o' was upregulated in LUAD. Univariate and multivariate logistic regression analysis indicated that high expression of 14-3-3o' predicted poor overall survival and progression-free survival of patients with LUAD. Furthermore, in vivo and in vitro experiments demonstrated that overexpression of 14-3-3o' markedly promoted cell proliferation, colony formation, anchorage-independent growth and tumor growth, whereas 14-3-3o' depletion produced the opposite effects. Of note, 14-3-3o' was identified as an independent prognostic factor for patients with LUAD. Collectively, the present results revealed that high expression of 14-3-3o' may serve as an independent biomarker, contributing to poor prognosis and progression of LUAD.